903 related articles for article (PubMed ID: 17572498)
1. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
Quigley HA; Friedman DS; Hahn SR
Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
[TBL] [Abstract][Full Text] [Related]
2. Gathering evidence from claims data: caveats.
Coleman AL
Ophthalmology; 2007 Sep; 114(9):1597-8. PubMed ID: 17822970
[No Abstract] [Full Text] [Related]
3. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).
Friedman DS; Quigley HA; Gelb L; Tan J; Margolis J; Shah SN; Kim EE; Zimmerman T; Hahn SR
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5052-7. PubMed ID: 17962457
[TBL] [Abstract][Full Text] [Related]
4. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002.
Stein JD; Ayyagari P; Sloan FA; Lee PP
Ophthalmology; 2008 Aug; 115(8):1315-9, 1319.e1. PubMed ID: 18321581
[TBL] [Abstract][Full Text] [Related]
5. Physician beliefs and behaviors related to glaucoma treatment adherence: the Glaucoma Adherence and Persistency Study.
Gelb L; Friedman DS; Quigley HA; Lyon DW; Tan J; Kim EE; Zimmerman TJ; Hahn SR
J Glaucoma; 2008 Dec; 17(8):690-8. PubMed ID: 19092468
[TBL] [Abstract][Full Text] [Related]
6. Persistence and adherence with topical glaucoma therapy.
Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
[TBL] [Abstract][Full Text] [Related]
7. [Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France].
Bron A; Nordmann JP; Baudouin C; Rouland JF; Kadi A; Sartral M
J Fr Ophtalmol; 2003 Nov; 26(9):895-903. PubMed ID: 14631273
[TBL] [Abstract][Full Text] [Related]
8. A gap analysis approach to assess patient persistence with glaucoma medication.
Lee PP; Walt JG; Chiang TH; Guckian A; Keener J
Am J Ophthalmol; 2007 Oct; 144(4):520-4. PubMed ID: 17692273
[TBL] [Abstract][Full Text] [Related]
9. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
[TBL] [Abstract][Full Text] [Related]
10. Accounting for restart rates in evaluating persistence with ocular hypotensives.
Schwartz GF; Platt R; Reardon G; Mychaskiw MA
Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
[TBL] [Abstract][Full Text] [Related]
11. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
Robin AL; Novack GD; Covert DW; Crockett RS; Marcic TS
Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
[TBL] [Abstract][Full Text] [Related]
12. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study.
Friedman DS; Hahn SR; Gelb L; Tan J; Shah SN; Kim EE; Zimmerman TJ; Quigley HA
Ophthalmology; 2008 Aug; 115(8):1320-7, 1327.e1-3. PubMed ID: 18321582
[TBL] [Abstract][Full Text] [Related]
13. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Robin AL; Covert D
Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
[TBL] [Abstract][Full Text] [Related]
14. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
15. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
[TBL] [Abstract][Full Text] [Related]
16. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
[TBL] [Abstract][Full Text] [Related]
17. Comparison of optic nerve head topography and visual field in eyes with open-angle and angle-closure glaucoma.
Boland MV; Zhang L; Broman AT; Jampel HD; Quigley HA
Ophthalmology; 2008 Feb; 115(2):239-245.e2. PubMed ID: 18082888
[TBL] [Abstract][Full Text] [Related]
18. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
19. Determinants of adherence to glaucoma medical therapy in a long-term patient population.
Djafari F; Lesk MR; Harasymowycz PJ; Desjardins D; Lachaine J
J Glaucoma; 2009 Mar; 18(3):238-43. PubMed ID: 19295380
[TBL] [Abstract][Full Text] [Related]
20. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
Hahn SR; Kotak S; Tan J; Kim E
Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
